Amneal Pharmaceuticals (AMRX) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Amneal Pharmaceuticals

NasdaqGS•Healthcare•Drug Manufacturers - Specialty & Generic

$18.32+0.04(<0.01%)Market open

Market Cap

$5.85B

P/E

37.2x

P/S

1.9x

P/B

177.1x

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with a focus on central nervous system and endocrine disorders, including Parkinson's disease. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT, which is use for the treatment of Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

How this company scores

GoodMetricSide Score: 60/100

Strongest: Profitability (20/25); weakest: Balance Sheet & Red Flags (8/25).

Profitability20/25

Growth19/25

Balance Sheet & Red Flags8/25

Cash & Earnings Quality13/25

Strengths

High ROERising earningsCash-backed earningsProfit converts from growth

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 37.2x5y range 25.7x – 87.0x

Currently below its 9-quarter median.

P/S · 1.9x5y range 0.1x – 1.9x

Currently above its 20-quarter median.

P/B · 177.1x5y range 0.7x – 177.1x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

Some Concerns

Earnings Quality

Watch

FCF/Net Income has dropped below 0.7x in 4 quarters — monitor for earnings quality deterioration.

Cash Burn

Watch

FCF turned negative in 3 of the last 8 quarters — occasional cash consumption.

Price & Volume

Market Cap $5.85B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $3.12B
Q. Revenue: $796.20M
TTM EBITDA: $648.21M
TTM Op. Income: $453.92M
Q. Op. Income: $129.77M
TTM Net Income: $157.36M
Q. Net Income: $57.66M
EPS: $0.18
Shares Out.: $319.20M

$3.12B in TTM revenue grew 9.3% YoY, reaching $796.20M last quarter. TTM EBITDA of $648.21M and TTM operating income of $453.92M show growth is flowing through to the bottom line. TTM net income of $157.36M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 42.0%
EBITDA Margin: 22.3%
Op. Margin: 16.3%
Net Margin: 7.2%

Op. margin of 16.3% is up 0.9% YoY — cost efficiency is improving. Net margin at 7.2% and gross margin of 42.0% show how much of each revenue dollar survives to profit. Over the past year, operating margin is up 6% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 37.2x
P/S Ratio: 1.9x
P/B Ratio: 177.1x

At 37.2x P/E, the stock trades above typical market levels — the market expects above-average growth. P/S of 1.9x and P/B of 177.1x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Over the past year, P/E is down 32% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $3.78B
Cash: $127.64M
Long-Term Debt: $2.56B
Book Value: $33.02M
D/E Ratio: 77.7
Debt/EBITDA: 14.4

With $3.78B in assets and $2.56B in long-term debt, D/E is 77.7and book value is $33.02M — elevated leverage, meaning significant financial risk in a downturn.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-21.24M
TTM Free Cash Flow: $127.83M
FCF Margin: 4.1%
FCF / Net Income: 0.8

TTM FCF of $127.83M on $-21.24M in operating cash flow. The FCF / Net Income ratio of 0.8x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has fallen for 2 consecutive quarters — a weakening trend.